FI962247L - Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät - Google Patents

Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät Download PDF

Info

Publication number
FI962247L
FI962247L FI962247A FI962247A FI962247L FI 962247 L FI962247 L FI 962247L FI 962247 A FI962247 A FI 962247A FI 962247 A FI962247 A FI 962247A FI 962247 L FI962247 L FI 962247L
Authority
FI
Finland
Prior art keywords
methods
dna encoding
modifying proteins
novel apoptosis
apoptosis
Prior art date
Application number
FI962247A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI962247A0 (fi
FI962247A7 (fi
Inventor
Michael C Kiefer
Philip J Barr
Original Assignee
Lxr Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lxr Biotechnology Inc filed Critical Lxr Biotechnology Inc
Publication of FI962247A0 publication Critical patent/FI962247A0/fi
Publication of FI962247A7 publication Critical patent/FI962247A7/fi
Publication of FI962247L publication Critical patent/FI962247L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
FI962247A 1993-11-30 1994-11-30 Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät FI962247L (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16006793A 1993-11-30 1993-11-30
US32015794A 1994-10-07 1994-10-07
PCT/US1994/013930 WO1995015084A1 (en) 1993-11-30 1994-11-30 Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
FI962247A0 FI962247A0 (fi) 1996-05-29
FI962247A7 FI962247A7 (fi) 1996-07-22
FI962247L true FI962247L (fi) 1996-07-22

Family

ID=26856568

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962247A FI962247L (fi) 1993-11-30 1994-11-30 Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät

Country Status (14)

Country Link
US (7) US6015687A (de)
EP (1) EP0731636B1 (de)
JP (4) JP4129055B2 (de)
CN (1) CN1139871A (de)
AT (1) ATE315643T1 (de)
AU (1) AU688839B2 (de)
CA (1) CA2177827C (de)
DE (1) DE69434614T2 (de)
ES (1) ES2256843T3 (de)
FI (1) FI962247L (de)
HU (1) HUT74276A (de)
NO (1) NO962188L (de)
NZ (1) NZ277946A (de)
WO (1) WO1995015084A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ277946A (en) * 1993-11-30 1998-03-25 Lxr Biotechnology Inc Apoptosis modulating protein and nucleotide sequence compositions using bcl-2 homologs termed cdn-1, cdn-2 and cdn3
US5998131A (en) * 1994-10-07 1999-12-07 Lxr Biotechnology, Inc. Screening methods for the identification of compounds capable of abrogating BaK-BHRF-1 protein interactions
JPH1189573A (ja) * 1994-10-14 1999-04-06 Yutaka Shindo アポトーシス関与遺伝子
CA2216856C (en) * 1995-04-20 2008-02-19 Lxr Biotechnology Inc. Methods of screening for therapeutic agents using novel apoptosis-modulating proteins
US6436639B1 (en) * 1997-02-18 2002-08-20 Tanox, Inc. Bak promoter expression system
US6441135B1 (en) 1997-03-20 2002-08-27 Tanox, Inc. Bak binding protein, DNA encoding the protein, and methods of use thereof
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6218144B1 (en) * 1997-06-30 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Costal2 genes and their uses
US6641998B2 (en) * 1997-10-10 2003-11-04 Stratagene Methods and kits to enrich for desired nucleic acid sequences
DE69937835T2 (de) * 1998-09-24 2009-01-02 Promega Corp., Madison Antikörper für apoptosemarker und anwendungsverfahren
US6570002B1 (en) 1999-02-26 2003-05-27 The Johns Hopkins University Inhibitor of programmed cell death
US6737511B1 (en) * 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
WO2001052639A1 (en) 2000-01-21 2001-07-26 Beth Israel Deaconess Medical Center Use of pro-apoptotic factors in treatment of atherosclerosis
AU2001276406A1 (en) * 2000-07-14 2002-01-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Apoptosis-inducing dna sequences
US20030170722A1 (en) * 2001-03-02 2003-09-11 Mcfadden Grant Methods and reagents for regulating apoptosis
EP1253200A1 (de) * 2001-04-25 2002-10-30 Société des Produits Nestlé S.A. Kakao-Polypeptide und ihre Anwendung zur Herstellung von Kakao- und Schokoladenaroma
US7635686B2 (en) * 2001-10-03 2009-12-22 Bioniche Life Sciences, Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
AU2003298014A1 (en) * 2002-12-04 2004-06-23 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
WO2004072225A2 (en) * 2003-02-12 2004-08-26 Ramot At Tel Aviv University Ltd. Transgenic fungi expressing bcl-2 and methods of using bcl-2 or portions thereof for improving biomass production, survival, longevity, stress resistance and pathogenicity of fungi
US7368428B2 (en) * 2003-06-23 2008-05-06 A&G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
EP1660010B1 (de) * 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Zusammensetzungen und verfahren zur wiederherstellung der empfänglichkeit für eine behandlung mit her2-antagonisten
PT2500360E (pt) * 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
US20130065312A1 (en) * 2009-11-03 2013-03-14 The Johns Hopkins University Method and composition for generating programmed cell death resistant algal cells
EP2418286A1 (de) * 2010-08-10 2012-02-15 QIAGEN GmbH Verbessertes Verfahren zur isothermalen Amplifikation von Nukleinsäuren
US20130166458A1 (en) * 2011-12-22 2013-06-27 Embraer S.A. System and method for remote and automatic assessment of structural damage and repair
US20230392166A1 (en) * 2020-10-21 2023-12-07 Wisconsin Alumni Research Foundation Anti-apoptotic vector and method of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5395767A (en) 1992-06-22 1995-03-07 Regents Of The University Of California Gene for ataxia-telangiectasia complementation group D (ATDC)
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US6083735A (en) 1993-06-24 2000-07-04 The General Hospital Corporation Programmed cell death genes and proteins
WO1995005738A1 (en) 1993-08-20 1995-03-02 Massachusetts Institute Of Technology Anticancer agents and apoptosis
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
NZ277946A (en) * 1993-11-30 1998-03-25 Lxr Biotechnology Inc Apoptosis modulating protein and nucleotide sequence compositions using bcl-2 homologs termed cdn-1, cdn-2 and cdn3
US5672686A (en) * 1994-08-09 1997-09-30 Immunogen, Inc. Bcl-Y - specific antibodies
CA2216856C (en) * 1995-04-20 2008-02-19 Lxr Biotechnology Inc. Methods of screening for therapeutic agents using novel apoptosis-modulating proteins
US5656725A (en) * 1995-05-12 1997-08-12 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7

Also Published As

Publication number Publication date
US6015687A (en) 2000-01-18
DE69434614T2 (de) 2006-10-05
JP2007252391A (ja) 2007-10-04
JP2009189377A (ja) 2009-08-27
ES2256843T3 (es) 2006-07-16
CA2177827C (en) 2007-08-28
US20030008837A1 (en) 2003-01-09
NO962188D0 (no) 1996-05-29
JP2006061159A (ja) 2006-03-09
US5770443A (en) 1998-06-23
EP0731636A1 (de) 1996-09-18
JPH09509567A (ja) 1997-09-30
FI962247A0 (fi) 1996-05-29
CA2177827A1 (en) 1995-06-08
AU688839B2 (en) 1998-03-19
HUT74276A (en) 1996-11-28
FI962247A7 (fi) 1996-07-22
ATE315643T1 (de) 2006-02-15
DE69434614D1 (de) 2006-04-06
CN1139871A (zh) 1997-01-08
NO962188L (no) 1996-07-23
JP4129055B2 (ja) 2008-07-30
NZ277946A (en) 1998-03-25
US7754418B2 (en) 2010-07-13
US7108989B2 (en) 2006-09-19
US20050164284A1 (en) 2005-07-28
US20070117748A1 (en) 2007-05-24
AU1335195A (en) 1995-06-19
HU9601448D0 (en) 1996-07-29
WO1995015084A1 (en) 1995-06-08
US6586395B1 (en) 2003-07-01
EP0731636B1 (de) 2006-01-11
EP0731636A4 (de) 1998-04-15
US6903195B1 (en) 2005-06-07

Similar Documents

Publication Publication Date Title
FI962247L (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
DE69407414D1 (de) Foerderung der braeunung mit dns-fragmenten
DE69434520D1 (de) Biotinylierung von proteinen
FI945166L (fi) Katalyttejä, niiden käyttömenetelmä ja menetelmä niiden valmistamiseksi
FI954648A7 (fi) Proteiinien erottaminen
FI955234L (fi) Entsyymidispersiot, niiden valmistaminen ja niitä sisältävät seokset
EP0760849A4 (de) Rekombinante, aud bpi und lbp basierende proteine, die für sie kodierenden nukleinsäuren, verfahren zu ihrer herstellung und ihre verwendung
GB9310472D0 (en) Phenylalanine-free protein and dna coding thereof
DK38989D0 (da) Dna-sekvens
FI951403L (fi) Polypeptidit, jotka liittyvät streptogramiinien biosynteesiin, näitä polypeptidejä koodittavat nukleotidisekvenssit, ja niiden käyttö
DE69433915D1 (de) MDC-Proteine und dafür kodierende DNS
FI920038A7 (fi) Lipaasia ja lipaasimodulaattoria koodaava DNA
FI863855A7 (fi) Sementtiseoksia ja menetelmä.
FI945227A7 (fi) Sykliset heksapeptidit, niiden valmistus ja käyttö
FI902803A7 (fi) DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä
BR9406536A (pt) Segmento de DNA que compreende gene codificador de proteína inseticida
FI960706A7 (fi) Uusi proteiini ja menetelmiä proteiinin valmistamiseksi
FI953457A0 (fi) Intsyymiä sisältävä granulaatti, sen valmistusmenetelmä ja sen käyttö
NO892948D0 (no) Modifiserte proteiner.
DK75393D0 (da) Production of protein
FI955537A7 (fi) Fibrinolyyttiset ja hyytymistä estävät proteiinit
FI946031L (fi) Kringleä sisältävien proteiinien puhdistus ja etenkin t-PA:n
FI954765L (fi) Deallylointireagenssi ja deallylointimenetelmä, jossa mainittua reagenssiä käytetään
DE69634206D1 (de) Sic protein von streptococcus, ein inhibitor der komplement-vermittelten lyse
DE68917536D1 (de) Methode zur Reduktion von aromatischen Amino-Gruppen.